# US 8,785,156 B2 · TLE3 as a marker for chemotherapy > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,785,156 B2 - Document ID: US8785156B2 - Status: Granted - Kind: B2 - Application number: 13/685,924 - Filed: 2012-11-27 - Published: 2013-03-28 - Granted: 2014-07-22 - Earliest claimed: 2007-11-30 - Assignees: Clarient Diagnostic Services, Inc. - Applicants: Clarient Diagnostic Services, Inc. - Inventors: Brian Z. Ring; Douglas T. Ross; Robert S. Seitz; Rodney A. Beck - Web page: https://patentgrep.com/patent/US8785156B2 ## CPC - G01N 33/57515: of the breast - A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine - A61K 31/519: ortho- or peri-condensed with heterocyclic rings - A61K 31/66: Phosphorus compounds - A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} - A61P 35/00: Antineoplastic agents - C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575) - G01N 33/57545: of the ovaries - G01N 33/6893: {related to diseases not provided for elsewhere} - C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism - G01N 2333/4703: Regulators; Modulating activity - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES ## Abstract Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer. ## Claims ### Claim 1 A method of treating breast, lung or ovarian cancer in a patient comprising administering to the patient in need thereof a taxane, wherein the patient's cancer has been previously identified to express TLE3 polypeptide. ### Claim 2 (depends on 1) The method of claim 1, wherein the patient's cancer is breast cancer. ### Claim 3 (depends on 2) The method of claim 2, wherein the patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers. ### Claim 4 (depends on 2) The method of claim 2, wherein the taxane is paclitaxel. ### Claim 5 (depends on 2) The method of claim 2, wherein the taxane is docetaxel. ### Claim 6 (depends on 1) The method of claim 1, wherein the patient's cancer is lung cancer. ### Claim 7 (depends on 6) The method of claim 6, wherein the taxane is paclitaxel. ### Claim 8 (depends on 6) The method of claim 6, wherein the taxane is docetaxel. ### Claim 9 (depends on 1) The method of claim 1, wherein the patient's cancer is ovarian cancer. ### Claim 10 (depends on 9) The method of claim 9, wherein the taxane is paclitaxel. ### Claim 11 (depends on 9) The method of claim 9, wherein the taxane is docetaxel. ### Claim 12 A method of treating breast, lung, or ovarian cancer in a patient, wherein the cancer has been identified as positive for TLE3 polypeptide expression, the method comprising administering a taxane to the patient. ### Claim 13 (depends on 12) The method of claim 12, wherein the cancer is breast cancer. ### Claim 14 (depends on 13) The method of claim 13, wherein the patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers. ### Claim 15 (depends on 13) The method of claim 13, wherein the taxane is paclitaxel. ### Claim 16 (depends on 13) The method of claim 13, wherein the taxane is docetaxel. ### Claim 17 (depends on 12) The method of claim 12, wherein the cancer is lung cancer. ### Claim 18 (depends on 17) The method of claim 17, wherein the taxane is paclitaxel. ### Claim 19 (depends on 17) The method of claim 17, wherein the taxane is docetaxel. ### Claim 20 (depends on 12) The method of claim 12, wherein the cancer is ovarian cancer. ### Claim 21 (depends on 20) The method of claim 20, wherein the taxane is paclitaxel. ### Claim 22 (depends on 20) The method of claim 20, wherein the taxane is docetaxel. ### Claim 23 A method of treating breast cancer in a patient, wherein the patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers and the cancer has been identified as positive for TLE3 polypeptide expression, the method comprising administering a taxane to the patient. ### Claim 24 (depends on 23) The method of claim 23, wherein the taxane is paclitaxel. ### Claim 25 (depends on 23) The method of claim 23, wherein the taxane is docetaxel. ### Claim 26 A method of treating lung or ovarian cancer in a patient, wherein the cancer has been identified as positive for TLE3 polypeptide expression, the method comprising administering a taxane to the patient. ### Claim 27 (depends on 26) The method of claim 26, wherein the taxane is paclitaxel. ### Claim 28 (depends on 26) The method of claim 26, wherein the taxane is docetaxel. ### Claim 29 (depends on 26) The method of claim 26, wherein the cancer is lung cancer. ### Claim 30 (depends on 26) The method of claim 26, wherein the cancer is ovarian cancer.